SecBot SecBot
Insider Cluster (2 insiders) ·Filed Nov 6, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed10d 7h ago
Insider cluster: 2 insiders, $155K total
Actionable Insight • Neutral

Insider sales are de minimis and largely under a 10b5-1 plan. No bearish signal; monitor next 10-Q for any change in fundamentals.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$314.15
T+0 close · Nov 6, 2026 · via day close
Latest settled
−3.96%
T+5 · $301.71
Vs SPY
−2.27%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $314.15entry
  2. T+1 · 7d ago +0.00%α +0.37% · $314.16
  3. T+5 · 18h ago −3.96%α −2.27% · $301.71
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two insiders at Ligand Pharmaceuticals sold shares in the week following the company's Q3 earnings beat and raised guidance. The CLO sold under a 10b5-1 plan, while a director sold without one. Total open-market sales of $155K are trivial relative to the $6.3B market cap (0.0025%), making this a routine liquidity event with no material signal.

Key Financial Metrics

Direction
selling
Total Value
$155.0K
Insiders
2

Key Facts

  • Two insiders sold shares: CLO Andrew Reardon (10b5-1 plan) and director Aryeh Jason (no plan)
  • Total open-market sales: $155K (0.0025% of $6.3B market cap)
  • Sales occurred 4-6 days after Q3 earnings beat and raised guidance
  • CLO Reardon also exercised 5,000 derivative shares at $0 and $52.27 on Nov 2 (non-cash events)
  • Director Jason sold 700 shares ($224K) on Nov 2 and 282 shares ($90K) on Nov 4

Financial Impact

Total open-market sales of $155K, immaterial relative to $6.3B market cap

insider ownership

Risk Factors

  • Director Jason's sale without a 10b5-1 plan could indicate personal liquidity needs, not a negative view
  • No material risk identified from this cluster

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-LGND-1794004938540

Track record

29 reports on LGND

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
  6. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
  7. Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Viewing Entry $314.15 Now $301.71 −3.96% settles Feb 5
  9. Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
  10. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
Showing 10 of 29

US Market Status

Market Closed · Opens in 8h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026